Instrument Inactif

Communiqués Tiger X Medical Inc Other OTC

Actions

US88677A1043

Cours en clôture Other OTC Autres places de cotation
- ^USD	-

07/06	BioCardia reçoit un brevet pour un cathéter d'administration biothérapeutique transendocardique ; les actions montent avant la cloche	MT
21/05	BioCardia va procéder à un regroupement d'actions à raison de 1 pour 15 ; les actions chutent après les heures de cotation	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

BioCardia Announces United States Patent Issuance on Intramyocardial Delivery of Cell Aggregates to the Heart Including Minimally Invasive Radial Artery Approach	07/06	AQ
BioCardia Announces Reverse Stock Split	21/05	AQ
BioCardia : Reports First Quarter 2024 Business Highlights and Financial Results	14/05	PU
BioCardia to Host Q1 2024 Financial Results and Corporate Update Conference Call on May 14, 2024	09/05	AQ
BioCardia’s CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial Results Show Patient Benefits in Important Outcomes	01/05	AQ
BioCardia Completes Enrollment of CardiAMP Cell Therapy for the Treatment of Chronic Myocardial Ischemia Trial Open Label Roll-In Cohort	25/04	AQ
BioCardia : Reports Fourth Quarter and Full Year 2023 Business Highlights and Financial Results	27/03	PU
BioCardia to Host 2023 Financial Results and Corporate Update Conference Call on March 27, 2024	20/03	AQ
BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership	13/03	AQ
BioCardia Announces CMS Approval of Coverage for CardiAMP Cell Therapy Confirmatory Phase III Heart Failure Study	12/03	AQ
BioCardia Reports Positive Interim Results from Phase III CardiAMP Cell Therapy Heart Failure Trial, with Compelling Data in Subgroup with Elevated NTproBNP Biomarker for Heart Failure	04/03	AQ
BioCardia Announces Activation of CardiAMP Heart Failure II Phase 3 Pivotal Study Recently Approved by FDA	08/02	AQ
BioCardia Announces Two Scientific Abstracts Have Been Accepted at the 2024 Technology and Heart Failure Therapeutics Conference	31/01	AQ
BioCardia Biotherapeutic Delivery and Morph Access Innovations Business Development Update for Shareholders	03/01	AQ
BioCardia Doses First Patient in CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells for the Treatment of Ischemic Heart Failure of Reduced Ejection Fraction	19/12	AQ
BioCardia Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes	18/12	AQ
BioCardia : Announces Expected CardiAMP Heart Failure Japan Approval Timeline Based on Pharmaceutical and Medical Device Agency Consultation Minutes - Form 8-K	18/12	PU
BioCardia : Material Event - Form 8-K	06/12	PU
BioCardia : Shareholder Meeting - Form 8-K	05/12	PU
BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval	29/11	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Tiger X Medical Inc Other OTC

Actions

US88677A1043

Communiqués

Filtres